TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06212024

Intervention type: BEHAVIORAL
Intervention: Mentalization Based Treatment-early
Description: MBT-early is an early intervention program for young people at risk for developing BPD that has been developed as an adaptation of MBT, an empirically supported treatment for BPD. MBT-early is a time-limited intervention that has been designed for early-stage BPD and focuses on improving personality functioning. MBT-early is a two-phase treatment that integrates interventions at the individual, family, and context level. MBT-early provides a combination of treatment modalities, including individual and family sessions, case management, and treatment reviews. Interventions are tailored to the specific needs of the young person and his/her family. The treatment consists of 16 weekly individual sessions, 3 family sessions, and case management. The initial treatment phase (16 weeks) is followed by a booster period (6 months) with 4 booster sessions. Since MBT-early involves a flexible approach, this standard package may be downscaled in cases of rapid improvement, or upscaled when needed.
Study: NCT04968990

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proton Beam Radiation (PBRT)
Description: The treatment approach with radiation therapy prescribed in this trial is designed to deliver highly conformal radiation therapy (proton beam radiation or intensity modulated photon radiation) to target volumes that are based on the burden of disease.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proton Beam Radiation (PBRT)
Description: The treatment approach with radiation therapy prescribed in this trial is designed to deliver highly conformal radiation therapy (proton beam radiation or intensity modulated photon radiation) to target volumes that are based on the burden of disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DD-4A Chemotherapy Regimen
Description: Patients will receive standard of care chemotherapy based on diagnosis and stage.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DD-4A Chemotherapy Regimen
Description: Patients will receive standard of care chemotherapy based on diagnosis and stage.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complete Surgical Resection
Description: Participants will undergo complete surgical resection at diagnosis or after 6-12 weeks of induction chemotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Resection
Description: Participants will undergo surgical resection at diagnosis or after 6-12 weeks of induction chemotherapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial Nephrectomy
Description: Participants will undergo partial nephrectomy after 6-12 weeks of induction chemotherapy.
Study: NCT06103591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The EmStop Embolic Protection System (EmStop System)
Description: The EmStop Embolic Protection System (EmStop System) is a catheter-based filter system that captures and removes debris dislodged during transcatheter aortic valve replacement (TAVR) procedures.
Study: NCT05682508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education group
Description: Based on the Health Belief Model, a educational booklet on diet and fluid control in individuals receiving hemodialysis treatment has been prepared. The training content consists of information on the structure and function of the kidneys, information about chronic renal failure, possible complications in case of non-adherence with the desired fluid control and diet, perceived benefits, the information on diet and fluid control consisted of perceived benefits, barriers, coping with barriers, perceived susceptibility in this regard, and information on the development of self-efficacy to improve dietary compliance and fluid control.~Individuals in the education group were given individual training by the researcher. The training was conducted in a single meeting of 20-30 minutes in the first hour when haemodialysis started and the patient's condition was stable.
Study: NCT06433791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbate-Meglumine
Description: Ascorbate, meglumine and sodium salt made by combining 375 mM sodium ascorbate,125 mM ascorbic acid and 125 mM meglumine in sterile water for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbate-Meglumine
Description: Ascorbate, meglumine and sodium salt made by combining 375 mM sodium ascorbate,125 mM ascorbic acid and 125 mM meglumine in sterile water for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbate-Meglumine
Description: Ascorbate, meglumine and sodium salt made by combining 375 mM sodium ascorbate,125 mM ascorbic acid and 125 mM meglumine in sterile water for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbate-Meglumine
Description: Ascorbate, meglumine and sodium salt made by combining 375 mM sodium ascorbate,125 mM ascorbic acid and 125 mM meglumine in sterile water for injection
Study: NCT04629508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itacitinib
Description: itacitinb Immediate Release (IR) will be dosed orally twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itacitinib
Description: itacitinb Immediate Release (IR) will be dosed orally twice a day
Study: NCT06211088

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: famotidine plus10ml normal saline
Description: to evaluate the difference of the gastric volume by quantitative measurements of gastric antrum preoperatively and postoperatively by using 5mg famotidine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 10ml normal saline
Description: to evaluate the difference of the gastric volume by quantitative measurements of gastric antrum preoperatively and postoperatively by placebo
Study: NCT06561295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Later Morning Timing of Spontaneous Breathing Trials
Description: Later Morning Group: Patients in this group will have their SBTs scheduled between 8:00 AM and 9:00 AM, closer to the time of day shift rounds.
Study: NCT06396039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986374
Description: Specified dose on specified days.
Study: NCT05298579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga exercises
Description: Yoga-based exercise training includes a warm-up and cool-down period for beginners

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga exercises
Description: Yoga-based exercise training includes a warm-up and cool-down period for beginners
Study: NCT04328714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells
Description: To determine the maximal dose, initially adult subjects will receive a single infusion of third party, freshly ex vivo expanded, IFNγ-primed MSCs at a dose of 2 x 106 cells/kg of ideal body weight on Day +1 (the day after infusion of the hematopoietic cell graft). The dose will be escalated to 5 x 106 and then 10 x 106 cells/kg. In absence of any dose limiting toxicity, 10 x 106 cells/kg will be accepted as the maximal dose.~Subsequent participants in the adult and pediatric cohorts will receive the maximal dose as determined by the initial adult participants.~Participants will receive the infusion in an inpatient setting. MSCs will be intravenously infused through a central line or a large bore peripheral IV using standard blood product tubing within 4 hours of release. The product will be infused by IV push or syringe pump over approximately 30-60 minutes or to gravity depending on product volume.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells
Description: To determine the maximal dose, initially adult subjects will receive a single infusion of third party, freshly ex vivo expanded, IFNγ-primed MSCs at a dose of 2 x 106 cells/kg of ideal body weight on Day +1 (the day after infusion of the hematopoietic cell graft). The dose will be escalated to 5 x 106 and then 10 x 106 cells/kg. In absence of any dose limiting toxicity, 10 x 106 cells/kg will be accepted as the maximal dose.~Subsequent participants in the adult and pediatric cohorts will receive the maximal dose as determined by the initial adult participants.~Participants will receive the infusion in an inpatient setting. MSCs will be intravenously infused through a central line or a large bore peripheral IV using standard blood product tubing within 4 hours of release. The product will be infused by IV push or syringe pump over approximately 30-60 minutes or to gravity depending on product volume.
Study: NCT05774353

Intervention type: OTHER
Group type: OTHER
Intervention: Patient questionnaire
Description: Patients included in the study will complete an online questionnaire (LimeSurvey).
Study: NCT06166654

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: 1. 500 mg IV bolus of acetazolamide at randomization (day 0) and repeated the next 3 mornings (day 1, day 2 and day 3). This arm will also receive a placebo- Metolazone tablet together with each acetazolamide-injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metolazone 2.5 MG
Description: 2. 2.5 mg oral Metolazone at randomization (day 0) and repeated the next 3 mornings (day 1, day 2 and day 3). This arm will also receive a placebo- acetazolamide injection together with each metolazone-tablet.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Double-placebo
Description: This arm will also receive both a placebo-acetazolamide injection together with a placebo-metolazone-tablet at randomization and repeated the next 3 mornings (day 1, day 2 and day 3).
Study: NCT05890833

Intervention type: DIAGNOSTIC_TEST
Intervention: The risk of falls
Description: Heel-Rise-Test, Chair-Rise Test, Semi-tandem stand, Trunk Rise Test, and Foot-tapping speed. Test battery two includes Timed Up and Go test, 10 Meter Walk Test, Six Minute Walk test, The Falls Efficacy Scale International FES-I, The Morse Fall Scale.
Study: NCT06329830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: 7.4 GBq (200 mCi) via IV infusion once every 6 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib abiraterone acetate
Description: Dual action drug tablet that is taken orally by the participant once per day in one of the following dose combinations depending on the cohort assignment and number of dose-limiting toxicities: 200 mg/1000 mg, 150 mg/1000 mg, 100 mg/1000 mg, 50 mg/500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg orally twice per day
Study: NCT05940103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR)
Description: AR headset - a device that the participants will wear over their head and eyes and will add holographic elements to a live view of workplace training scenario
Study: NCT05777486

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TikTok Ads - With Food
Description: TikTok posts from influencers promoting food.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TikTok Ads - Without Food
Description: TikTok posts from influencers who are not promoting food.
Study: NCT04786743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: endoscopic intervention
Description: performing endoscopy

Intervention type: OTHER
Group type: OTHER
Intervention: endoscopic intervention
Description: performing endoscopy
Study: NCT05467007

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: BioFire® Respiratory Panel 2.1-EZ
Description: BioFire RP2.1-EZ Panel uses a syndromic approach to quickly identify SARS-CoV-2, along with 18 additional viral and bacterial pathogens in patients suspected of SARS-CoV-2. This PCR test provides results in about 45 minutes.
Study: NCT06047561

Intervention type: RADIATION
Intervention: PET-CT
Description: PET combined with CT or MRI

Intervention type: RADIATION
Intervention: PET-CT
Description: PET combined with CT or MRI

Intervention type: RADIATION
Intervention: PET-CT
Description: PET combined with CT or MRI
Study: NCT06444659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Physical Activity Classes
Description: The intervention group received a 6 months adaptive physical activity intervention; the control group, on the other hand, continued their original regular physical activity programme for the same period of time and maintained their original lifestyle habits.
Study: NCT06398652

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMAB015
Description: Patients would receive 300 mg CMAB007 subcutaneous injections at week 0, 1, 2, 3, 4, 8 as induction therapy. Patients who obtain a 75% improvement relative to baseline in PASI scores would receive 300 mg CMAB007 subcutaneous injections every 4 weeks as maintain therapy, until the last treatment at week 48.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab
Description: Patients would receive 300 mg secukinumab subcutaneous injections at week 0, 1, 2, 3, 4, 8 as induction therapy. Patients who obtain a 75% improvement relative to baseline in PASI scores would receive 300 mg secukinumab subcutaneous injections every 4 weeks as maintain therapy, until the last treatment at week 48.
Study: NCT06008951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening to music
Description: All participants will listen to self-chosen or researcher-chosen music with noise-cancelling headphones (JBL Tune 770NC). The music will be administered for 20 minutes before participants receive increasing electric pain stimuli.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening to music
Description: All participants will listen to self-chosen or researcher-chosen music with noise-cancelling headphones (JBL Tune 770NC). The music will be administered for 20 minutes before participants receive increasing electric pain stimuli.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Listening to a podcast
Description: ln the control condition, participants will listen to a podcast with noise-cancelling headphones (JBL Tune 770NC). The podcast will be administered for 20 minutes before participants receive increasing electric pain stimuli.
Study: NCT04935606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual Care participants will receive their standard medical care as usual and all study assessments. Providers will not receive information about their drug use. To reduce Hawthorne effect biases and to mask the study's purpose, RAs will provide the Usual Care arm patients with a cancer screening booklet and have them view a cancer screening Video Doctor. Participants will receive re-contact calls (5 min) to provide attentional control for the Usual Care arm, motivate continued trial participation by reminding next research assessment and study incentives, update contact information, and address participation barriers, but do not provide intervention. At study end, Usual Care will receive the QUIT video doctor and drug use reduction booklet materials including overdose prevention materials and a list of clinic/community resources to help them reduce substance use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QUIT Intervention (doctor brief advice, video doctor, health coaching sessions at 2- and 6-weeks)
Description: QUIT's core components include:~1. patient screening with the WHO Alcohol Smoking and Substance Involvement Screening Test (ASSIST, score 4-26);~2. face-to-face brief clinician advice on reducing drug use (2-3 minutes);~3. video doctor reinforcing the clinician message;~4. drug use reduction brochure;~5. 2- and 6-week telephone health coaching sessions to enhance self-efficacy in reducing drug use, via motivational interviewing and cognitive behavior therapy (CBT) techniques (20-30 minutes).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QUIT-Mobile (QUIT Intervention plus weekly mobile-web app or text message weekly self-monitoring, automated feedback over 12 months)
Description: The QUIT-Mobile intervention includes QUIT's core components and adds:~1. SMS/IVR/mobile-app self-monitoring survey prompts twice-weekly during the QUIT coaching through 6 weeks, and then weekly self-monitoring and automated feedback via SMS/IVR/app through 12-months.~2. Web-based dashboards will be used by coaches for monitoring of patients' self-monitoring data to enhance 2- and 6-week coaching sessions and for monitoring during the post-coaching self-management and monitoring period from 7-weeks to 12-months and intervening accordingly. The mobile platform will provide the same intervention functions (self-monitoring surveys and feedback messages) and robust data transfer protocols across three mobile technology platforms.
Study: NCT06222554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MoveMend Health
Description: Software-based therapeutic tool that offers gamified exercises and activities. The device is designed for deployment on tablets. The core purpose of the device is to augment patient engagement and participation in their own rehabilitation by providing additional therapeutic interventions between formal occupational therapy sessions.
Study: NCT05854966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI 613
Description: For INDUCTION therapy (14 day cycles): Devimistat (CPI-613) 2,500mg/m2, days 1-5, 14-day cycles for cycles 1 and 2 only.~For MAINTENANCE therapy (21 day cycles): Devimistat (CPI-613) 2,500mg/m2, days 1-5, 21-day cycles until progression, intolerable toxicity or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: For INDUCTION therapy (14 day cycles):~Metformin 500 mg daily (taken with meals), days 1-2 for cycle 1 only. Metformin 500 mg twice daily (taken with meals), days 3-14 for cycle 1 only. Metformin 1,000 mg daily (taken with meals), days 1-2 for cycle 2 only. Metformin 1,000 mg twice daily (taken with meals) days 3-4 for cycle 2 only.~For MAINTENANCE therapy (21 day cycles): Metformin 1,000 mg twice daily (taken with meals) days 1-21 until progression, intolerable toxicity or withdrawal of consent

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood draws
Description: In the first induction cycle ONLY, extra blood will be withdrawn on day 1 before and after treatment with CPI-613 research purposes. Additional blood draws on days 2-5 to test blood before receiving CPI-613 to make sure participants are healthy enough to receive CPI-613.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow biopsy
Description: After the second induction cycle participants will have a bone marrow biopsy. After this biopsy, participants will have other bone marrow biopsies every 3 months for the next year. After the first year, participants may have a bone marrow biopsy if the treating physician feels it is necessary.
Study: NCT06088823

Intervention type: OTHER
Intervention: Heart surgery
Description: Adult cardiac surgery

Intervention type: OTHER
Intervention: Heart surgery
Description: Adult cardiac surgery
Study: NCT06496620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: Solrikitug low dose
Description: Solrikitug subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: Solrikitug high dose
Description: Solrikitug subcutaneous injection

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo subcutaneous injection
Study: NCT04872413

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood, saliva or tissue sample collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-Up
Description: Undergo follow-up
Study: NCT05974722

Intervention type: DEVICE
Group type: OTHER
Intervention: OviTex Mesh
Description: Patient will receive Ovitex Mesh (TELA Bio)

Intervention type: OTHER
Group type: OTHER
Intervention: Pledgeted sutures
Description: Patient will receive pledgeted sutures
Study: NCT05176899

Intervention type: DEVICE
Intervention: Use of Eko CORE electronic stethoscope
Description: Recording of heart sounds using electronic stethoscope
Study: NCT05734768

Intervention type: BEHAVIORAL
Intervention: State-Trait Anxiety Inventory - Y ou STAI-Y
Description: Questionnaire

Intervention type: BEHAVIORAL
Intervention: State-Trait Anxiety Inventory - Y ou STAI-Y
Description: Questionnaire
Study: NCT06406751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MI Paste
Description: Sterile swabs will be used to collect plaque from under the subject's upper denture (when the denture is removed) and the subject's mouth tissues. This will be used for genomic DNA, bacteria analysis, and fungus analysis. Subjects will also apply 1 cubic centimeter of MI Paste to the fitting surface on a daily basis for 7 days. Afterward, subjects will return to the clinic for another sterile swab to be collected.
Study: NCT06512584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PJ009
Description: subcutaneous injections, 0.05 mg/kg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PJ009 Placebo
Description: subcutaneous injections, once daily
Study: NCT06083779

Intervention type: GENETIC
Intervention: low-depth whole-genome sequencing technology
Description: the characteristics of five cfDNA fragments based on low-depth whole-genome sequencing technology (WGS)
Study: NCT05162781

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Caregiver Coaching
Description: One or more family members of the participant will receive coaching on how to best support the participant in carrying out the in-home components of the intervention.
Study: NCT06093477

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fast-Dissolve Melatonin Pill
Description: Participants in this arm will take 3mg of melatonin in fast-dissolve pill form daily during the specified study period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fast-Dissolve Placebo Pill
Description: Participants in this arm will take 3mg of placebo in fast-dissolve pill form daily during the specified study period.
Study: NCT05062785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Description: This will be given intranasally at differing doses depending on study day. A total of 11 possible doses will be tested, ranging from 0 to 1000 U insulin. Each volunteer will come for 5 visits.~On the first treatment day participants will receive placebo (sterile water) in each nostril followed by a 4-hour observation period. After this observation period participants will receive the initial dose of insulin squirted in each nostril followed by a a 4 hour observation period. Participants will have at least 7 days in between the other 4 visits. Subsequent visits will include increased doses of insulin (depending on how this is tolerated) and will take approximately 4 hours at these visits.
Study: NCT05491265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent Kangaroo mother care
Description: Skin to skin contact between mother and preterm newborn between gestational age 28 weeks to 36+6 weeks for three sessions per day ,each contact session of two hours .
Study: NCT06244628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: Oral administration of Iguratimod, 25mg twice daily